Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG.

Mol Cancer Ther. 2018 Aug;17(8):1739-1751. doi: 10.1158/1535-7163.MCT-17-1095. Epub 2018 May 9.

2.

Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity.

Dheilly E, Majocchi S, Moine V, Didelot G, Broyer L, Calloud S, Malinge P, Chatel L, Ferlin WG, Kosco-Vilbois MH, Fischer N, Masternak K.

Antibodies (Basel). 2018 Jan 3;7(1). pii: E3. doi: 10.3390/antib7010003.

3.

Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.

Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R, Rousseau F, Ferlin W, Kosco-Vilbois M, Fischer N, Masternak K.

Mol Ther. 2017 Feb 1;25(2):523-533. doi: 10.1016/j.ymthe.2016.11.006.

4.

Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG.

Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, Raimondi S, Malinge P, Di Grazia L, Rousseau F, Poitevin Y, Calloud S, Cayatte PA, Alcoz M, Pontini G, Fagète S, Broyer L, Corbier M, Schrag D, Didelot G, Bosson N, Costes N, Cons L, Buatois V, Johnson Z, Ferlin W, Masternak K, Kosco-Vilbois M.

Nat Commun. 2015 Feb 12;6:6113. doi: 10.1038/ncomms7113.

5.

CCR7 is involved in the migration of neutrophils to lymph nodes.

Beauvillain C, Cunin P, Doni A, Scotet M, Jaillon S, Loiry ML, Magistrelli G, Masternak K, Chevailler A, Delneste Y, Jeannin P.

Blood. 2011 Jan 27;117(4):1196-204. doi: 10.1182/blood-2009-11-254490. Epub 2010 Nov 4.

PMID:
21051556
6.
7.

Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA.

Krawczyk M, Peyraud N, Rybtsova N, Masternak K, Bucher P, Barras E, Reith W.

J Immunol. 2004 Nov 15;173(10):6200-10.

8.

The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA.

Muhlethaler-Mottet A, Krawczyk M, Masternak K, Spilianakis C, Kretsovali A, Papamatheakis J, Reith W.

J Biol Chem. 2004 Sep 24;279(39):40529-35. Epub 2004 Jul 22.

9.
10.

Chromatin remodeling and extragenic transcription at the MHC class II locus control region.

Masternak K, Peyraud N, Krawczyk M, Barras E, Reith W.

Nat Immunol. 2003 Feb;4(2):132-7. Epub 2003 Jan 13.

PMID:
12524537
11.
12.

MHC class II deficiency: a disease of gene regulation.

Villard J, Masternak K, Lisowska-Grospierre B, Fischer A, Reith W.

Medicine (Baltimore). 2001 Nov;80(6):405-18. Review. No abstract available.

13.

Maturation of dendritic cells is accompanied by rapid transcriptional silencing of class II transactivator (CIITA) expression.

Landmann S, Mühlethaler-Mottet A, Bernasconi L, Suter T, Waldburger JM, Masternak K, Arrighi JF, Hauser C, Fontana A, Reith W.

J Exp Med. 2001 Aug 20;194(4):379-91.

14.

Molecular genetics of the Bare lymphocyte syndrome.

Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Reith W.

Rev Immunogenet. 2000;2(2):267-82. Review.

PMID:
11258423
15.

Lessons from the bare lymphocyte syndrome: molecular mechanisms regulating MHC class II expression.

Waldburger JM, Masternak K, Muhlethaler-Mottet A, Villard J, Peretti M, Landmann S, Reith W.

Immunol Rev. 2000 Dec;178:148-65. Review.

PMID:
11213800
16.
17.

CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Masternak K, Muhlethaler-Mottet A, Villard J, Zufferey M, Steimle V, Reith W.

Genes Dev. 2000 May 1;14(9):1156-66.

18.

Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II-deficient patients belonging to complementation group B.

Wiszniewski W, Fondaneche MC, Lambert N, Masternak K, Picard C, Notarangelo L, Schwartz K, Bal J, Reith W, Alcaide C, de Saint Basile G, Fischer A, Lisowska-Grospierre B.

Immunogenetics. 2000 Apr;51(4-5):261-7.

PMID:
10803838
19.
20.

The molecular basis of MHC class II deficiency and transcriptional control of MHC class II gene expression.

Reith W, Muhlethaler-Mottet A, Masternak K, Villard J, Mach B.

Microbes Infect. 1999 Sep;1(11):839-46. Review. No abstract available.

PMID:
10614000
21.

A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients.

Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, Sanchez JC, Hochstrasser DF, Mach B, Reith W.

Nat Genet. 1998 Nov;20(3):273-7.

PMID:
9806546
22.

Infectious human papillomavirus type 18 pseudovirions.

Stauffer Y, Raj K, Masternak K, Beard P.

J Mol Biol. 1998 Oct 30;283(3):529-36.

PMID:
9784363
23.
24.

Reactivation of transcription from a vaccinia virus early promoter late in infection.

Garcés J, Masternak K, Kunz B, Wittek R.

J Virol. 1993 Sep;67(9):5394-401.

Supplemental Content

Loading ...
Support Center